Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | LIG1 | P18858 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800168 | 0.99 | L3MBTL1 (0.47) | L3MBTL1CYP3A4TP53HTTFOLH1 | |
| SCHEMBL22799660 | 0.94 | CYP3A4 (0.46) | L3MBTL1CYP3A4TP53HTTFOLH1 | |
| SCHEMBL22799778 | 0.90 | CYP3A4 (0.50) | L3MBTL1CYP3A4TP53HTTFOLH1 | |
| SCHEMBL22800185 | 0.87 | ALDH1A1 (0.47) | L3MBTL1CYP3A4TP53HTTFOLH1 | |
| SCHEMBL22799631 | 0.85 | ALDH1A1 (0.46) | L3MBTL1CYP3A4HTTALDH1A1TSHR | |
| SCHEMBL22800173 | 0.85 | ALDH1A1 (0.46) | L3MBTL1CYP3A4HTTALDH1A1TSHR | |
| SCHEMBL10448129 | 0.80 | ALDH1A1 (0.60) | L3MBTL1CYP3A4HTTALDH1A1TSHR | |
| SCHEMBL27398691 | 0.79 | TP53 (0.48) | TP53HTTFOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL6393227 | 0.79 | TP53 (0.48) | TP53HTTFOLH1MRGPRX4ALDH1A1 | |
| SCHEMBL4564517 | 0.79 | TSHR (0.54) | L3MBTL1CYP3A4TP53HTTFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | L3MBTL1 3891/4885CYP3A4 4538/4885TP53 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.